Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Novartis AG ADR is a pharmaceuticals business based in the US. Novartis AG ADR shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Novartis AG ADR employs 108,000 staff and has a trailing 12-month revenue of around $52.3 billion.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $85.85 |
|---|---|
| 52-week range | $74.09 - $94.26 |
| 50-day moving average | $90.21 |
| 200-day moving average | $85.30 |
| Wall St. target price | $104.25 |
| PE ratio | 9.0175 |
| Dividend yield | $3.39 (3.71%) |
| Earnings per share (TTM) | $9.70 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $85.85 from 2023-02-03
| 1 week (2023-01-27) | -4.07% |
|---|---|
| 1 month (2023-01-04) | -6.52% |
| 3 months (2022-11-04) | 5.05% |
| 6 months (2022-08-04) | 0.73% |
| 1 year (2022-02-04) | -0.50% |
|---|---|
| 2 years (2021-02-04) | -5.27% |
| 3 years (2020-02-04) | 95.1 |
| 5 years (2018-02-02) | 87.2164 |
Valuing Novartis AG ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis AG ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis AG ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Novartis AG ADR shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novartis AG ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.7688. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis AG ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis AG ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19.4 billion.
The EBITDA is a measure of a Novartis AG ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $52.3 billion |
|---|---|
| Operating margin TTM | 27.17% |
| Gross profit TTM | $37.4 billion |
| Return on assets TTM | 7.41% |
| Return on equity TTM | 36.99% |
| Profit margin | 41.71% |
| Book value | $28.28 |
| Market capitalisation | $189.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 72.98% of net profits
Recently Novartis AG ADR has paid out, on average, around 72.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.71% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis AG ADR shareholders could enjoy a 3.71% return on their shares, in the form of dividend payments. In Novartis AG ADR's case, that would currently equate to about $3.39 per share.
Novartis AG ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novartis AG ADR's most recent dividend payout was on 16 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 7 March 2022 (the "ex-dividend date").
Novartis AG ADR's shares were split on a 1116:1000 basis on 8 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis AG ADR shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis AG ADR shares which in turn could have impacted Novartis AG ADR's share price.
Over the last 12 months, Novartis AG ADR's shares have ranged in value from as little as $74.09 up to $94.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis AG ADR's is 0.4929. This would suggest that Novartis AG ADR's shares are less volatile than average (for this exchange).
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.